Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT03595150

Diclofenac for Prevention of Post-ERC Pancreatitis

The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and which patients develop pancreatitis after the ERCP.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

About this study

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a procedure commonly performed for diagnosing changes in the bile ducts or managing outflow obstruction. Although ERCP may in most cases be performed safely, there is a risk of developing acute pancreatitis following the procedure. The risk has been estimated to 5-10%, with an increased risk in women, younger patients and in case the cannulation is difficult.

Phospholipase 2 is crucial in the pathogenesis of acute pancreatitis. As Diclofenac is a potent inhibitor of Phospholipase 2, it has been suggested that it may be used for prevention of post-ERCP pancreatitis. There is some evidence for the effectiveness of Diclofenac, but more studies are needed to confirm that it reduces the risk of post-ERCP pancreatitis.

In order to test whether Diclofenac reduces the risk for post-ERCP pancreatitis, a register-based randomized controlled study is planned. The study will be conducted embedded in the Swedish Register for Gallstone Surgery and ERCP (GallRiks). GallRiks includes data corresponding to the eligibility criteria as well as outcome measures. GallRiks will also be used to record which patients have been screened for inclusion.

Patients who meet the eligibility criteria are invited to the study. If they accept inclusion, they are randomized to 100 mg Diclofenac prior to the ERCP or np prophylaxis. No blinding is done.

The aim is to include 1000 patients. When 500 patients have been included, an interim analysis will be performed, comparing the incidence of pancreatitis and mortality in the two groups. A retrospective review of the patient records will be performed for those who develop pancreatitis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing ERCP

Exclusion criteria

  • Decision to perform ERCP taken intraoperatively
  • Intolerance/allergy against NSAID
  • Patients taking NSAID daily
  • Severe cardiac fail (ASA>4)
  • Kidney failure (GFR<30 ml/min)
  • Coagulation disorder
  • History of peptic ulcer bleeding
  • History of abdominoperineal resection
  • Pregnancy
  • Patients who do not understand Swedish

Treatment and study plan

Diclofenac

Drug

Diclofenac rectally given before the ERCP to prevent pancreatitis

Primary outcomes

  1. Post-ERCP pancreatitis

    Time frame: Within 30 days post-ERCP

    Acute pancreatitis recorded in GallRiks by responsible endoscopist or surgeon. According to GallRiks criteria pancreatitis includes elevated amylase and abdominal pain of an intensity that hospital stay is warranted.

Secondary outcomes

  1. Adverse drug reactions

    Time frame: Within 30 days post-ERCP

    Kidney failure, gastroduodenal ulcer or gastrointestinal bleeding

  2. Mortality

    Time frame: Within 30 days post-ERCP

    Death within 30 days after ERCP

Study contacts

Contact information is provided by the study sponsor or research team.

Gabriel Sandblom, Ass Prof

CONTACT

[email protected]

+46704158218

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Uppsala University

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jul 23, 2018
Registry last updated
Aug 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.